| Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study N Epperla, RL Welkie, P Torka, G Shouse, R Karmali, L Shea, ... Journal of Hematology & Oncology 16 (1), 1-6, 2023 | 6 | 2023 |
| Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study N Epperla, Q Zhao, R Karmali, P Torka, L Shea, TS Oh, ... Blood Advances 7 (17), 5038-5046, 2023 | 4 | 2023 |
| COVID vaccine antibody responses in patients with hematologic malignancies in a myeloid enriched cohort: a better antibody response in patients with myeloid malignancies than B … SY Goksu, J Rolwes, N Premnath, P Patel, R Ikpefan, G Kaur, ... Blood 138, 4134, 2021 | 2 | 2021 |
| Pre-Lymphodepletion Endothelial Activation and Stress Index As a Predictor of Clinical Outcomes in B-Cell Maturation Antigen CAR T Therapy for Multiple Myeloma J Lee, HV Upreti, A Sannareddy, H Reves, L Turer, P Abraham, Y Liu, ... Transplantation and Cellular Therapy 30 (2), S221-S222, 2024 | 1 | 2024 |
| Impact of circulating lymphoma cells at diagnosis on outcomes in patients with marginal zone lymphoma: a multicenter cohort study K Annunzio, NS Grover, RL Welkie, P Torka, MP Watkins, ... Blood Advances 7 (22), 6839-6843, 2023 | 1 | 2023 |
| Incidence of Invasive Fungal Infections in CAR T-Cell Therapy Recipients: A Single Center Retrospective Analysis. A Sannareddy, J Lee, HV Upreti, L Turer, JM Anderson, H Reves, ... Transplantation and Cellular Therapy 30 (2), S430, 2024 | | 2024 |
| Assessing the Predictive Value of Pre-Lymphodepletion and Infusion Endothelial Activation and Stress Index in CD19-Directed CAR-T Therapy for B-Cell Lymphoma HV Upreti, J Lee, A Sannareddy, H Reves, L Turer, P Abraham, Y Liu, ... Transplantation and Cellular Therapy, Official Publication of the American …, 2024 | | 2024 |
| Impact of Diagnosis to Treatment Interval on Outcomes in Patients with Newly Diagnosed Marginal Zone Lymphoma-a US Multisite Study N Epperla, K Annunzio, GP Shouse, NS Grover, P Torka, MP Watkins, ... Blood 142, 5159, 2023 | | 2023 |
| Impact of Maintenance Rituximab Following First-Line Systemic Therapy on Outcomes in Patients with Marginal Zone Lymphoma: Real-World Evidence from 10 US Centers N Epperla, K Annunzio, GP Shouse, NS Grover, P Torka, MP Watkins, ... Blood 142, 5147, 2023 | | 2023 |
| Outcomes in Patients with Classical Hodgkin Lymphoma Refractory or Intolerant to Brentuximab Vedotin and Anti-PD-1 Therapy: Real World Analysis from 14 US Academic Centers T Voorhees, E McLaughlin, P Torka, JA Florindez, TK Moyo, H Reves, ... Blood 142, 3061, 2023 | | 2023 |
| Allogeneic Stem Cell Transplant and CD30 Directed CART Cell Therapies Are Associated with Improved Survival in Classical Hodgkin Lymphoma Refractory or Intolerant to … T Voorhees, NS Grover, E McLaughlin, JA Florindez, TK Moyo, H Reves, ... Blood 142, 900, 2023 | | 2023 |
| Impact of Large Cells and Ki-67% on Outcomes in Patients with Newly Diagnosed Marginal Zone Lymphoma-Results from a Multicenter Cohort Study N Epperla, NS Grover, K Annunzio, MP Watkins, P Torka, R Karmali, ... Blood 142, 266, 2023 | | 2023 |
| Utilization and Barriers to Stem Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma: A ‘Real-World’Study of Treatment Patterns and Outcomes at a Safety-Net Versus a … S Dong, H Reves, YL Liu, R Kainthla, A Afrough, J Alvarenga, ... Blood 142, 2417, 2023 | | 2023 |
| P-111 Overall survival trends in young (< 55 years) transplant-inaccessible multiple myeloma patients treated at a safety net hospital system S Dong, A Sannareddy, R Sankarasubramanian, H Reves, U Khan, ... Clinical Lymphoma Myeloma and Leukemia 23, S95-S96, 2023 | | 2023 |
| P-121 Real world outcomes of undocumented multiple myeloma patients: a safety net hospital experience A Sannareddy, S Dong, R Sankarasubramanian, U Khan, H Reves, ... Clinical Lymphoma Myeloma and Leukemia 23, S102, 2023 | | 2023 |
| POSTER: HL-456 A Retrospective Analysis of Impact of EBV Status on Outcomes in Hodgkin Lymphoma E Yilmaz, H Reves, A Afrough, J Alvarenga, L Anderson Jr, R Collins, ... Clinical Lymphoma Myeloma and Leukemia 23, S198, 2023 | | 2023 |
| HL-456 A Retrospective Analysis of Impact of EBV Status on Outcomes in Hodgkin Lymphoma E Yilmaz, H Reves, A Afrough, J Alvarenga, L Anderson Jr, R Collins, ... Clinical Lymphoma Myeloma and Leukemia 23, S412, 2023 | | 2023 |
| SALVAGE TREATMENTS FOR RELAPSED/REFRACTORY SECONDARY CNS LYMPHOMA IN THE CAR T ERA: A REAL‐WORLD COMPARISON AM Patel, M Muquith, H Reves, A Afrough, RH Collins, LD Anderson Jr, ... Hematological Oncology 41, 789-790, 2023 | | 2023 |
| Impact of the Affordable Care Act and Medicaid Expansion on Insurance Coverage and Outcomes in Patients with HIV‐associated Aggressive B‐cell Non‐Hodgkin Lymphomas N Premnath, H Reves, U Pandey, J Anderson, A Afrough, LD Anderson, ... Hematological Oncology 41, 243-244, 2023 | | 2023 |
| Factors Associated with Increased Risk of Major Cardiovascular Events for Patients Undergoing CAR T Therapy H Reves, M Eljalby, A Rao, A Chandra, K Zhang, M Muquith, M Jackson, ... Hematological Oncology 41, 537-537, 2023 | | 2023 |
Praveen Ramakrishnan GeethakumariUniversity of Texas Southwestern Medical Center, Dallas, TXVerified email at utsouthwestern.edu
